HR Execs on the Move

VistaGen

www.vistagen.com

 
VistaGen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. VistaGen`s clinical-stage candidates are targeting multiple forms of anxiety and depression. They belong to a new class of drugs known as pherines, which are odorless, tasteless, neuroactive steroids that bind to distinct receptors on chemosensory neurons in the nasal passages and can impact the limbic amygdala without systemic uptake ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.vistagen.com
  • 343 Allerton Avenue
    South San Francisco, CA USA 94080
  • Phone: 650.577.3600

Executives

Name Title Contact Details
Jerrold Dotson
Vice President, Chief Financial Officer, and Secretary Profile
Cindy Anderson
Chief Financial Officer Profile

Similar Companies

Saranas

Early Bird is the first and only FDA-approved bleed detection system for peri and post-procedural monitoring of endovascular procedures.

Physician Partner

Physician Partner is a Newbury Park, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

The Morel Company

A new, innovative product that allows a single caregiver to reposition a patient up in bed in less than ten seconds with the simple push of a button. Learn more here.

Luscinia Health

Luscinia Health is a Houston, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Santen

At Santen, we`re innovating therapies to improve the quality of life for patients worldwide. Our single focus in ophthalmology enables us to challenge unmet needs in the field—through passionate research, successful collaboration, and clarity of commitment. With over 120 years of investigative insight, Santen remains committed to the discovery, exploration, and development of ophthalmic therapies. Now, and into the future. As a global company, Santen is often expanding to accommodate new and evolving initiatives in ophthalmic research, regulatory management, production, marketing, or distribution. Our clinical development network now spans three continents, with centers in EMEA (Europe, the Middle East and Africa), Japan, and the United States.